Glysure CEO to Present Clinical Trial Updates at Fall Medtech Industry Conferences
GlySure Limited, developer of in-hospital continuous glucose monitoring (CGM) systems, will update the industry on its progress toward U.S. and European regulatory trials at two leading MedTech conferences this fall. GlySure CEO Christopher Jones will speak at the AdvaMed 2012 MedTech Conference on October 2 in Boston, and at the Medical Devices Summit Europe on November 14 in Dublin.
Tight Glycemic Control (TGC) in the Intensive Care Unit (ICU) has been shown to improve outcomes, reduce mortality and cut the cost of care.
GlySure recently conducted human use trials that prove its system can continuously measure glucose levels across the entire human physiological range with an extremely high degree of accuracy and repeatability, which is key to effectively implementing TGC. The company is now preparing for its European and U.S. clinical regulatory trials.
The Advanced Medical Technology Association (AdvaMed) has selected GlySure as one of 70 medical device companies to present at its annual conference, which is attended by nearly 2,000 global MedTech executives, policy-makers, financiers, media and industry stakeholders. At the event, Jones will present the results of GlySure's latest clinical trials and outline the company's plans for CE and FDA regulatory trials in the coming months.
The producers of the 2012 Medical Devices Summit Europe have chosen Jones as one of 25 key MedTech leaders to share his insights on the global medical device industry. As a CEO with experience running both U.S. and European device companies, Jones will discuss "Strategies and Lessons Learned in International Distribution".
About GlySure: GlySure has developed a continuous intravascular glucose monitoring system using a proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU). The company has demonstrated through ICU testing highly accurate sensors, which can provide continuous glucose readings throughout the length of a patient's stay in the ICU. GlySure was founded in 2006, it is based in Abingdon, Oxfordshire, England and it has 20 employees. The company's products are not approved for use in the U.S. or Europe.
http://www.glysure.com  Media Contact: Kara Della Vecchia, KDV Communications, Inc. Tel: +1-508-314-3127. email@example.com  SOURCE GlySure Limited -0- 09/25/2012 CO: GlySure Limited ST: United States of America United Kingdom IN: ADV MLM PUB SU: TDS PRN -- UK201209241304 -- 0000 09/25/2012 11:00:00 EDT http://www.prnewswire.c